title: Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
abstract: We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 and 2012. Two propensity score-matched sample cohorts were created. We found that the addition of paclitaxel as a second intraperitoneal agent on a 3-week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin-based regimen. If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.
authors.affiliation: Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, 11221, Taiwan, China.|Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, 11217, Taiwan, China.
authors.forename: Yen-Hou
authors.initials: YH
authors.lastname: Chang
authors.affiliation: Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, 40705, Taiwan, China.|Institute of Biomedical Sciences, National Chung Hsing University, Taichung, 40227, Taiwan, China.|Rong-Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, 40227, Taiwan, China.|Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, 11217, Taiwan, China.
authors.forename: Chien-Hsing
authors.initials: CH
authors.lastname: Lu
authors.affiliation: Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, 11221, Taiwan, China.|Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, 11217, Taiwan, China.
authors.forename: Ming-Shyen
authors.initials: MS
authors.lastname: Yen
authors.affiliation: Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, 11221, Taiwan, China.|Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, 11217, Taiwan, China.
authors.forename: Wai-Hou
authors.initials: WH
authors.lastname: Lee
authors.affiliation: Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, 11221, Taiwan, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Chang
authors.affiliation: Department of Healthcare Management, Yuanpei University, Hsinchu, 30015, Taiwan, China. wpchang@mail.ypu.edu.tw.
authors.forename: Wei-Pin
authors.initials: WP
authors.lastname: Chang
authors.affiliation: Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, 11221, Taiwan, China. cmjuang@gmail.com.|Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, 11217, Taiwan, China. cmjuang@gmail.com.
authors.forename: Chi-Mu
authors.initials: CM
authors.lastname: Chuang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D065426:Cytoreduction Surgical Procedures; D004334:Drug Administration Schedule; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage* / Q000627:therapeutic use; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D057216:Propensity Score; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D002945:Cisplatin
keywords: Clinical trials; Epithelial ovarian, tubal, and peritoneal cancer; Intraperitoneal chemotherapy; Propensity score; Survival